Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Site Partners LLC

Neither a doctor nor a teaching hospital

Research payments

$8,190,681

1,011 payments

Through program year 2025, Clinical Site Partners LLC is reported as receiving $8,190,681 in research payments, across 1,011 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $1,982,745 605
2024 Research $2,843,819 182
2023 Research $1,960,989 97
2022 Research $1,100,843 60
2021 Research $302,285 67

Breakdown

Who paid Research payments · program years 2021–2025
  1. Pfizer Inc. $3,938,991 194 payments
  2. Eli Lilly and Company $1,651,953 34 payments
  3. GlaxoSmithKline, LLC. $771,948 230 payments
  4. Boehringer Ingelheim International GmbH $470,529 310 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $438,341 51 payments
  6. Moderna TX, Inc. $215,152 15 payments
  7. Biogen, Inc. $156,309 4 payments
  8. Boehringer Ingelheim Pharma GmbH & Co.KG $127,763 13 payments
  9. AbbVie, Inc. $97,964 25 payments
  10. Roche Products Limited $82,819 14 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $1,663,280 51 payments
  2. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,200,332 95 payments
  3. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $581,462 22 payments
  4. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $449,148 7 payments
  5. A Study of Retatrutide (Ly3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity Or Overweight (Triumph-2) $395,428 6 payments
  6. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight With Weight Related Comorbidities (Attain-1) $387,519 2 payments
  7. EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $330,092 271 payments
  8. A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlle $301,956 133 payments
  9. A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $290,319 13 payments
  10. Obesity Long term safety in patients with CV risk $225,966 1 payment
What the money was spent on Research payments · program years 2021–2025
  1. Other $17,406 13 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record